Axitinib (Inlyta™)

Status: Currently a NF2 Clinical Trial

Synonyms:

Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736,
UNII-C9LVQ0YUXG, AG013736, S1005_Selleck,
AG-013736, AG-13736

Trade Name:

Inlyta™

Pharmaceutical Company

Pfizer

Legal Status:

℞ - Prescription/Under Clinical Trial

Treatment By:

Pill - Oral

Tumor Target:

Vestibular Schwannoma

Protein Target:

TKI and VEGF Inhibitor

NF2 Trials:

Recruiting Trial: NCT02129647

Formula:

C₂₂H₁₈N₄OS

ChemSpider:

4953153

PubChem:

CID 6450551

Reccomendations:

• Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
• Take Axitinib at night instead of the morning to prevent fatigue.

Other Known Uses

• Breast Cancer
• Renal Cell Carcinoma (RCC)
• In Research for: Mesothelioma

Side Effects

• High Blood Pressure/Nosebleeds
• Diarrhea
• Fatigue, Tiredness
• Decrease in Appetite
• Nausea, Vomiting
• Hoarseness, Dry Thrroat
• Skin Conditions, Dry Skin and Blisters
• Constipation

Sources

1. Petrilli, Alejandra M., et al. "Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells." Oncotarget 8.19 (2017): 31666. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458238/ | DOI: doi:10.18632/oncotarget.15912
2. Reveal, AI-Enabled Phenotypic Screens. "Clinically Relevant Drugs." (2012) Source: https://recursionpharma.com/wp-content/uploads/2017/09/AI-Enabled_Pheno-9_25_2017v24.pdf
3. Meric-Bernstam, Funda, et al. "A decision support framework for genomically informed investigational cancer therapy." Journal of the National Cancer Institute 107.7 (2015): djv098. Source: https://academic.oup.com/jnci/article/107/7/djv098/913288 | DOI: 10.1093/jnci/djv098
4. Karajannis, Matthias A., and Rosalie E. Ferner. "Neurofibromatosis-related tumors: emerging biology and therapies." Current opinion in pediatrics 27.1 (2015): 26. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374132/ | DOI: 10.1097/MOP.0000000000000169
5. Shaw, Adam. "Diagnosis and Management of Hereditary Meningioma and Vestibular Schwannoma." Rare Hereditary Cancers. Springer, Cham, 2016. 17-27. Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2 | DOI: 10.1007/978-3-319-29998-3_2
6. Widemann, Brigitte C., and Scott R. Plotkin. "Consensus for NF clinical trials Recommendations of the REiNS collaboration (Supplement II)." (2016): S1-S3. Source: https://link.springer.com/chapter/10.1007/978-3-319-29998-3_2